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ABSTRACT: Mass spectrometry (MS) is one of the primary
techniques used for large-scale analysis of small molecules in
metabolomics studies. To date, there has been little data
format standardization in this ﬁeld, as diﬀerent software
packages export results in diﬀerent formats represented in
XML or plain text, making data sharing, database deposition,
and reanalysis highly challenging. Working within the
consortia of the Metabolomics Standards Initiative, Proteo-
mics Standards Initiative, and the Metabolomics Society, we
have created mzTab-M to act as a common output format
from analytical approaches using MS on small molecules. The
format has been developed over several years, with input from
a wide range of stakeholders. mzTab-M is a simple tab-separated text format, but importantly, the structure is highly
standardized through the design of a detailed speciﬁcation document, tightly coupled to validation software, and a mandatory
controlled vocabulary of terms to populate it. The format is able to represent ﬁnal quantiﬁcation values from analyses, as well as
the evidence trail in terms of features measured directly from MS (e.g., LC-MS, GC-MS, DIMS, etc.) and diﬀerent types of
approaches used to identify molecules. mzTab-M allows for ambiguity in the identiﬁcation of molecules to be communicated
clearly to readers of the ﬁles (both people and software). There are several implementations of the format available, and we
anticipate widespread adoption in the ﬁeld.
■ INTRODUCTION
It is now commonplace for high-throughput quantitative
technologies to be used for analysis of biological, biomedical,
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and environmental samples. Technologies include those for
measurements of gene expression using microarrays or RNA
sequencing (transcriptomics), proteins by mass spectrometry
(MS, proteomics), and MS or nuclear magnetic resonance
(NMR) spectroscopy for measuring small molecules/metabo-
lites (metabolomics) and lipids (lipidomics). These methods
can provide the source data for systems biology/medicine
investigations into the complex network of interactions that
reﬂect both their functional and dysfunctional states, as well as
reﬂect nutritional and environmental impacts. There is now an
accepted principle in scientiﬁc research that data should bemade
openly and easily accessible to allow groups other than the initial
data generators to verify the ﬁndings or search for new
interpretations. Such guidelines are now commonly referred to
as the “FAIR” principles, data being ﬁndable, accessible,
interoperable, and reusable.1 Furthermore, data from omics
experiments are typically expensive to generate and often have
potential uses beyond their initial purpose, including in meta-
analyses, in data integration, or for testing and assisting in the
development of new software. In omics research, there is always
some heterogeneity in the approaches taken in diﬀerent
laboratories, such as diﬀerent instrument platforms or analysis
software, which usually have their own ﬁle formats. To allow
data sets to be open for reuse generally requires the formulation
of nonproprietary data formats, or more ideally, agreed data
standards to which diﬀerent producers of data must adhere.
Without agreed standards (or ubiquitous formats originating
from one package), data reuse is highly challenging, since
informatics groups would need to write ﬁle format converters for
every possible source of data, as well as keep these converters
updated whenever data-producing software makes a format
change. This scenario makes development of analysis software
or a speciﬁc usage of public databases very challenging.
In a typical MS-based metabolomics/lipidomics pipeline,
samples are analyzed by liquid or gas chromatography, coupled
to MS (LC-MS/GC-MS), or by direct infusion (DIMS).
Measurement of molecular intensity is typically done via
software that detects features formed from isotopic patterns
(or single peaks) along the time axis. For LC-MS, ionization can
be performed in either positive or negative mode to produce
protonated or deprotonated ions. It is also common for ion
adducts to be formed, including metal adducts (Na+, K+), which
have the same time elution proﬁle but diﬀerent m/z values.
Many software packages perform adduct grouping, such that
quantiﬁcation values are reported both for individual features, as
well as for the summed abundance across diﬀerent adduct forms
assumed to have come from the same starting molecule. For
quantiﬁcation across diﬀerent samples, software may perform
retention time alignment to ensure that the same features are
quantiﬁed in each sample. In GC-MS, analysis is performed on
volatile molecules and, in some cases, a derivatization step is
applied to increase the volatility of compounds of interest.
Molecular identiﬁcation remains challenging in metabolo-
mics. Typically, some combination of the following steps can
assist with identiﬁcation via searching a pre-existing library or
database: accurate neutral mass, the relative abundance of
isotopomers, the retention time, masses of fragmentation
products (MS/MS and MSn spectra), collisional cross section
for platforms with ion mobility, etc. (see the reviews in refs 2−4
for more details). In the case ofMS/MS andMSn fragmentation,
the spectra can be compared against an in-house spectral library
or databases storing reference spectra for molecules including
Metlin,5 The Human Metabolome Database,6 Global Natural
Products Social Molecular Networking7 (GNPS), MassBank,8
and others (see ref 9 for a review) or analyzed by in silico
identiﬁcation software.10
It is common in all approaches for many molecules to remain
unannotated or for ambiguity to remain: i.e., software provides a
list of possible molecules for each MS feature. Reporting
standards and guidelines on these certainties have been
developed in several communities.11,12 Following quantiﬁcation
(and identiﬁcation), statistical analysis usually proceeds via
univariate approaches, e.g. to ﬁnd diﬀerentially expressed
molecules between conditions, or multivariate/machine learn-
ing approaches to explore structure within the data and ﬁnd
molecules that can separate sample groups and thus act as
potential biomarkers.
There exists a wide range of software, both free and
commercial, for processing MS data for metabolomics/
lipidomics.13,14 Most software produces output data in a unique
ﬁle format, annotated to diﬀerent levels of detail, often with the
description of preprocessing procedures followed implicit rather
than speciﬁed, making it highly challenging to compare or
integrate the results of diﬀerent pipelines. For public data
sharing, there are several databases that host data sets in support
of publications or community data sets, including the European
Bioinformatics Institute (EMBL-EBI) MetaboLights database15
and the NIH Metabolomics Workbench.16
In this work, we describe a data standard for MS-based
metabolomics analytical pipelines, called mzTab-M, which
captures the downstream results of analysis (i.e., excluding raw
data), suitable for statistical analysis, result visualization, or
submission to a public repository in support of a publication.
The standard has been developed in a joint and open process
between members of the Metabolomics Standards Initiative
(MSI),17 the Metabolomics Society Data Standards Task
Group, and the Proteomics Standards Initiative (PSI), which
had originally developed the mzTab format on which it is
based.18 There are several related and complementary eﬀorts,
which include eﬀorts to deﬁneminimum reporting requirements
for diﬀerent aspects of metabolomics.11,19 There is also general
agreement among standards groups (MSI, Metabolomics
Society) to promote the use of the PSI’s mzML format for raw
data storage.20 mzML is an XML-based standard for MS data,
either for proﬁle data as recorded directly from the instrument or
for centroided data (peak picked in them/z domain). The freely
available ProteoWizard software embeds software libraries from
several vendors of MS instruments, enabling the conversion of
vendor raw ﬁles into mzML.21 For NMR metabolomics, the
recently released nmrML standard follows a design principle
similar to that of mzML, capturing NMR spectra and some
metadata within an XML-based standard.22 For the description
of study design, experimental metadata, and sample processing
parameters, the ISA framework,23 while generally applicable to
all types of experimental design, has been particularly taken up
by the metabolomics ﬁeld. The PSI previously developed the
mzTab format (version 1.0) to act as a simple format for
quantiﬁed and/or identiﬁed peptides and proteins in MS
workﬂows.18 mzTab version 1.0 also has a section to allow small-
molecule data to be captured. However, the data model was
rather simple and did not cover some important use cases for
metabolomics/lipidomics and, as a result, it has not been
extensively used for small molecules or lipids. The development
of mzTab-M has thus branched oﬀ from the original mzTab
format development, and we report it here as a new standard for
metabolomics called mzTab-M (“version 2.0” to diﬀerentiate it
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from mzTab version 1.0). It follows design principles similar to
those of mzTab 1.0, but it is not backward compatible.
■ METHODS
The mzTab-M format was designed in a process that was open
to any interested parties. All associated materials and code for
processing and validating ﬁles are fully open source and are
hosted on GitHub (https://github.com/HUPO-PSI/mzTab).
mzTab-M started from the design of mzTab version 1.0 format
but was further developed to support the speciﬁc needs of
metabolomics (see the Supporting Information for more details
on the relationship). The development took place via face-to-
Figure 1.Overall structure of an mzTab-M ﬁle. (A)Metadata about the experiment, describing experimental design (study variables and assays), links
to other ﬁles, etc.. (B) The small molecule (SML) table, capturing “ﬁnal” results table: i.e., overall calculated quantiﬁcation value (and identity where
known) of a metabolite. (C) Quantiﬁcation value in each (aligned) MS run for MS1 features: e.g., mapped to individual adducts or charge states of a
molecule. (D) Evidence supporting identiﬁcation (with ambiguity if needed) for molecules, using CV terms for scores/statistics where available.
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face workshops and regular conference calls. The speciﬁcations
have been submitted to a formal document process for
anonymous review, overseen by an editor commissioned jointly
between the PSI and the Metabolomics Society. The mzTab-M
format is deﬁned by the speciﬁcation document and example
ﬁles that demonstrate how to encode certain features (see the
GitHub repository). The speciﬁcation document describes the
overall structure of the format: what tables must be present, what
columns and rows must be present in those tables, and what
terminology is allowed as data values. For various aspects of
metadata, the standard enforces (and can be checked by
validation software) that controlled vocabulary (CV) terms are
used (e.g. for names of software, databases, parameters, statistics,
etc.), which can be sourced from the PSI-MS CV26 (https://
www.ebi.ac.uk/ols/ontologies/ms), as well as other CVs where
appropriate.
■ RESULTS AND DISCUSSION
mzTab-M has been designed to act as a single data format for
metabolomics and lipidomics, including an appropriate level of
detail about the “ﬁnal” results: i.e., molecules quantiﬁed across
samples. The format also contains the ability to represent
“intermediate” or supporting data, including the evidence trail
for identiﬁcations from software (scores or statistics), as well as
the quantiﬁcation values derived directly from MS: i.e., prior to
any adduct grouping or summarization steps. The format is
represented as tab-separated text, meaning that it can be loaded
directly into a spreadsheet editor or into statistical software such
as R or SPSS for downstream analysis and visualization, without
any need for coding, and can thus replace the use of tables (e.g.,
in pdf or Excel format) of supplementary data in support of
publications. It is also relatively straightforward for informatics
groups to develop software to add support for the standard to
existing software.
The mzTab-M format consists of four cross-referenced data
tables (Figure 1): metadata (MTD), small molecule (SML),
small molecule feature (SMF) and the small molecule evidence
(SME). The MTD and SML tables are mandatory, and for a ﬁle
to contain any evidence about howmolecules were quantiﬁed or
identiﬁed by software, all four tables must be present. The tables
must follow the order MTD, SML, SMF, and SME, with a blank
line separating each table. The structure of each table, in terms of
the rows and columns thatmust be present, is tightly speciﬁed, as
explained in the following sections and formally in the mzTab-M
speciﬁcation document.
Metadata (MTD) Table. The metadata table has multiple
rows and exactly three columns (Figure 1A). Each row must
contain (1) “MTD”, (2) a parameter name, and (3) the
parameter value. The types of parameters that must or may be
present are described in the speciﬁcation document, and allowed
values from CVs are deﬁned in a mapping ﬁle. The MTD table
must report at least a simple speciﬁcation of the experimental
design, in terms of the number of diﬀerent measurements (i.e.,
usually the count of MS runs) and the groupings of those MS
Figure 2. Simple experimental designs in mzTab-M can be represented using a combination of the elements study_variable (SV), assay, ms_run, and
sample. Quantitative values can be reported in ﬁles for SVs and assays. (A) SV is intended to capture diﬀerent groups of replicates, which might have
resulted from diﬀerent levels of a given variable: e.g. control versus treated (represented as 2 SVs) and n time points over a treatment course (as n SVs).
(B) assay captures ameasurement made about amolecule (small molecule/lipid) wheremultiple assays within the same SV are taken to be replicates of
some kind (biological or technical). (C)ms_run captures a single run on anMS instrument. (D) Samples are optional in mzTab, since the quantitative
software may often be unaware of the biological samples that have been analyzed. If that information is available, references from assay to the same
(technical, upper half) or diﬀerent (biological, bottom half) samples are used to describe the type of replication performed.
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runs (i.e., experimental factors or groups) over which statistical
analysis may be done. These values then inform the number of
columns present in SML and SMF tables for which (relative or
absolute) quantitative values are reported. The following
concepts are speciﬁed in the MTD table so that they can be
referenced and reused elsewhere in the ﬁle:
• Assay: the application of a measurement about the sample
(in this case through MS), producing values about small
molecules or lipids. One assay is typically mapped to one
ms_run element (see below), although the diﬀerentiation
between assay and ms_run is present to provide a
mechanism for grouping multiple MS runs together if the
sample has been fractionated and diﬀerent fractions run
on the instrument to increase coverage. The MTD table
gives the count of assays with locally unique identiﬁers, so
that they can be referenced by other elements.
• ms_run: an MS run is eﬀectively one run on an MS
instrument (e.g., by LC-MS, GC-MS, DIMS, etc.) and can
be referenced from assay elements in diﬀerent contexts.
When an ISA-Tab document from mzTab-M is
referenced, ms_run should be matched with the ISA
“Assay Name” values found in an ISA “Assay Table” ﬁle
(https://isa-specs.readthedocs.io/en/latest/isatab.html).
• Sample: a biological material that has been analyzed, to
which descriptors of species, cell/tissue type, etc. can be
attached. Samples are not mandatory, since some software
packages that will produce mzTab-M ﬁles cannot
determine what type of sample was analyzed (e.g.,
whether biological or technical replication was per-
formed), although it is noted that, without such
annotations, downstream statistical analysis of the results
will often not be possible.
• study_variable: a “study_variable” (SV) element repre-
sents a grouping of replicates for which a quantitative
value can be reported, for example following averaging of
values from individual assays. More accurately, a “study_-
variable” element usually represents a level of some
particular experimental variable, such as the value of time
within a time course, dose of a drug, intervention
performed on samples, etc. In other contexts, this concept
is named diﬀerently: e.g., “Factor Value” in ISA format.
Clear deﬁnitions of biological and technical replicates are
diﬃcult to provide, as the commonly used terminologies are
somewhat dependent upon the biological domain. However, we
use the following general deﬁnitions in mzTab-M: biological
replicates represent cases when diﬀerent samples are analyzed by
MS, and technical replicates represent cases where the same
samples are analyzed multiple times by MS. As illustrated in
Figure 2, a simple form of the experimental design can be
captured in mzTab-M using a combination of assay, “study_-
variable”, and “sample”. In a complex, nested design, linkages
between diﬀerent study variables are not explicitly modeled but
captured through the annotated values, as shown in the
Supporting Information.
The MTD table also has the (optional) capability to capture
additional metadata that can be useful to interpret the study,
such as limited details about the sample processing steps
performed, the MS instrument, software and parameters,
contact details for the study producers, etc. However, it is
acknowledged that other formats may capture such details, such
as referenced mzML (including instrument information and
parameters), other MS data ﬁle formats, or ISA-Tab ﬁles
(containing experimental design and sample processing), which
may be more appropriate locations for such information.
Small Molecule (SML) Table. The small molecule (SML)
table (Figure 1B) is intended to capture the “ﬁnal” results of the
study in terms of molecules that have been quantiﬁed (with
identiﬁcation data, where available). If diﬀerent adduct forms or
fragments of a molecule have been observed as diﬀerent MS
features, it is common that feature grouping is performed, and
the SML table should contain the ﬁnal quantitative values after
summarization. Thus, SML could be viewed as the equivalent of
tabular results presented in a paper for the molecules quantiﬁed
in diﬀerent samples. For survey-type data, it is also possible to
report quantities as “null”, while still reporting identiﬁcation
evidence, as supported by the SME table.
The header row has “SMH” in the ﬁrst column, followed by an
ordered set of column headers. After the header row, each row
reports one molecule, with the ﬁrst cell containing “SML”,
followed by the data values for each speciﬁed column. The
columns include a unique local identiﬁer for the molecule
(SML_ID), followed by a cell (SMF_ID_REFS) containing
references to features in the SMF table. The referenced features
are the diﬀerent adduct forms or in-source fragments of the
molecular features actually detected by MS. The next set of
columns provides diﬀerent ways to identify the molecule
(database_identifer, chemical_formula, smiles, inchi, chemical_-
name, uri, theoretical_neutral_mass; see section Identif ication
evidence and ambiguity below).
The following columns report quantitative data for the n
assays (in n columns, where n is the count of assays reported in
MTD) and the m study_variable groups (in m columns) e.g. as
an average (e.g., mean) across assay values within that
study_variable. A value can also be provided for the variability
in the study_variable quantiﬁcation value reported e.g. a
standard error value. A parameter in MTD speciﬁes how to
interpret the quantitative values in these columns in terms of a
data type exported from a speciﬁc piece of software or where
appropriate, absolute values with units.
At the right-hand end of the SML table (and SMF and SME
tables), it is possible to include user-speciﬁed (optional)
columns, with a method for annotating that the columns refer
to the entire molecule, or the measurement of the molecule in
particular assays or study_variables. The user-speciﬁed columns
thus make mzTab-M extensible to support custom data types
not covered in the core model.
Small Molecule Feature (SMF) Table. The SMF table
contains data on what features were actually measured by the
instrument and quantiﬁed by software (Figure 1C). The header
row of the table has “SFH” in the ﬁrst cell, followed by a set of
columns. Each row of the table is one MS feature recorded
across diﬀerent runs, starting with the code “SMF”. It is assumed
that an alignment process has taken place so that the same
feature has been seen across diﬀerent runs, with missing values
handled as appropriate (see speciﬁcation document for guidance
on encoding nonaligned workﬂows). The next column
(SME_ID_REFS) is for referencing down to the ﬁnal table:
Small Molecule Evidence (SME) via a set of identiﬁer
references, as well as a code telling the ﬁle reader how to
interpret multiple references (SME_ID_REF_ambiguity_code),
explained in Identiﬁcation Evidence and Ambiguity.
The SMF table next contains information about the type of
adduct and charge state observed, the experimental m/z value,
the retention time of the feature (in a master or averaged run),
and a method for optionally specifying if a given isotopomer has
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been quantiﬁed (+1 or +2 peak, 13C peak, etc.) as used in some
isotopic labeling/ﬂux studies. The following columns represent
the quantitative data within each of the n assays recorded in the
MTD section. For SML, a parameter inMTD also describes how
to interpret the quantitative values recorded.
Small Molecule Evidence (SME) Table. The SME table
represents strands of potentially heterogeneous types of
evidence supporting the identiﬁcation of a molecule (Figure
1D). Each row contains the result of one identiﬁcation process
(library search, pattern match, manual curation, etc.). The
header of the table starts with “SEH” followed by a set of
columns. The second column is a local identiﬁer for a row of
evidence (SME_ID), followed by a local identiﬁer for the input
data to the process (evidence_input_id). evidence_input_id is
needed for the cases where diﬀerent rows of evidence are
reported for the same input data (MS2 spectrum, accurate mass
+ retention time, isotope pattern, etc.). They can be linked by
sharing the same value for evidence_input_id. As in the SML
table, a set of columns exists to specify the molecular identity
from a variety of sources or identiﬁer types (database_identifer,
chemical_formula, smiles, inchi, chemical_name, uri). The
experimental m/z value of the feature, the charge, and the
theoretical m/z value (e.g., from a database) can be recorded,
along with scores or conﬁdence measures coming from the
software used to support the identiﬁcation. If a fragmentation
spectrum has been used, there is a mechanism for referencing
the exact spectrum in the source ﬁle (e.g., mzML ﬁle) and the
MS level of the input data to the identiﬁcation process.
Identiﬁcation Evidence and Ambiguity. Small-molecule
identiﬁcation is a well-known challenge in MS metabolomics,
and even more so in MS lipidomics, where complete structural
elucidation of molecules is often not possible. Diﬀerent levels of
“identiﬁcation” might be possible, ranging from having the
accurate mass only, the chemical formula, a list of possible
identiﬁers to molecules in a database (with the same or diﬀerent
formula), or a complete molecular structure resolved: e.g., if a
complementary technique such as NMR has been used. mzTab-
M has been designed to accommodate all the diﬀerent
possibilities in a simple yet ﬂexible structure (Figure 3). For
further details on how identiﬁcations of lipids and other
compound classes can be represented see the Supporting
Information.
In a row of the ﬁnal results (SML table), the export software
can include one or more identiﬁers from external databases: e.g.,
“CHEBI:16811” where the preﬁx is deﬁned in MTD as
referencing the ChEBI database24 (with a URL) and the
identiﬁer is the ChEBI unique identiﬁer (in this case for
methionine). Similarly, the speciﬁcation allows for the chemical
formula in standard notation, simpliﬁed molecular-input line-
entry system (SMILES25), or InChi26 to be provided. In all
cases, if ambiguity has not been resolved, then a Pipe “|”
separated list of identiﬁers can be provided in the same cell.
There are several measures for describing the conﬁdence of
identiﬁcation, including the use of reliability codes such as those
developed by theMSI11,12 and the score or conﬁdence measures
from identiﬁcation software where available.
To trace the evidence source, references via the features (SMF
table) and on to the SME table should be provided. In the case
that adduct grouping (i.e., multiple SMF rows) has been
performed prior to identiﬁcation, then the diﬀerent SMF rows
will reference the same SME rows. At the SME level, if there are
diﬀerent rows from the same input data (e.g., diﬀerent database
matches), then it is expected that the SMF element(s) references
multiple SME elements that share the same value for
evidence_input_id. It is also possible to report diﬀerent evidence
streams to support identiﬁcation, such as searches in diﬀerent
libraries. As such, SMF rows can reference multiple SME
elements carrying diﬀerent values of evidence_input_id. Given
that these two cases would both result in multiple SME
identiﬁers referenced from an SMF row, an extra code can be
Figure 3. (A) The summary level (SML) reports the ﬁnal assumed identiﬁcations, allowing for ambiguity by including “|” separated results in the
relevant columns. (B) The feature level (SMF) does not explicitly report identiﬁcations but references down to the SME level. Ambiguity is propagated
via referencing multiple SME rows with diﬀerent identiﬁcation results. (C) One SME row represents a single possible identiﬁcation from some input
evidence. Multiple identiﬁcations from the same input data share the same value for evidence_input_id. Ambiguity can be captured by diﬀerent rows for
the same input data.
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provided at the SMF level (SME_ID_REF_ambiguity_code)
containing values to diﬀerentiate whether ambiguity has been
resolved or still remains (see the speciﬁcation document for a
full description).
Using CVs and File Validation.mzTab-M extensively uses
CVs to provide unambiguous terms for annotation. For
parameters relating to MS and associated processing, CV
terms should generally be sourced from the PSI MS CV.27
Several other CVs are recommended for describing details about
sample types, species taxonomy, sample preparation, etc. (see
the speciﬁcation document). To ensure that valid CV terms are
used, we have extended the concept of the PSI semantic
validation framework.28 The framework includes a mapping ﬁle
that states the groups of CV terms allowed at each position in
mzTab-M, enabling the list of terms to expand over time,
without changes in the standard or software. New terms can be
added straightforwardly by making a request on a mailing list:
e.g., for a term describing new software, scores, or statistics. A
crucial part of the standard is therefore a validator to ensure that
ﬁles exported from diﬀerent packages fulﬁll the rules deﬁned in
the speciﬁcation, so that they can be read without error by other
software. We have developed validation software for mzTab-M,
available from jmzTab (project: https://github.com/lifs-tools/
jmzTab-m), which checks not only that the structure of the ﬁle is
correct but also that valid and correct CV terms have been used
throughout.
Implementation in Software and Databases. The
speciﬁcations have been veriﬁed by both PSI and MSI formal
review processes, from which the stable version (mzTab-M 2.0)
has been released. It is not expected that there will be changes to
the format for several years to allow implementations to be
developed. A reference implementation with parser, writer, and
validator (in jmzTab-m) has been developed in Java (as for
mzTab 1.029). jmzTab-m provides an OpenAPI 2.0 compatible
API model that serves as the basis for automatic model
generation in a wide number of programming languages (C++,
JavaScript, R, Python), reducing the burden of implementation.
The library provides parsing, validation, and writing of mzTab-
M ﬁles and object models. A web-based application (https://
apps.lifs.isas.de/mztabvalidator/) provides a user-friendly user
interface to perform standard and semantic validation and to
display validation results. Additional implementations are under
development in software including XCMS,30 Progenesis QI
(Waters), Lipid Data Analyzer,31 OpenMS,32 and Metabo-
Lights.15 Over the coming years, we will be promoting the
implementation of the standard in a wide variety of both open-
source and commercial software to act as a universal standard for
metabolomics and lipidomics.
■ CONCLUSIONS
We have developed mzTab-M for metabolomics data
representation and sharing. The standard has been developed
in an open process with widespread consultation of diﬀerent
approaches taken in the ﬁeld and involvement of software teams
from academic research groups as well as industry. The standard
has undergone a rigorous peer review process by both the MSI
and PSI to ensure that the resulting standard is of high quality
and is stable. The standard is expected to remain stable for
several years, except for improvements to documentation and
extensions to the CV, allowing research groups and commercial
developers to invest time in the implementation. We also
encourage other groups interested in standardizing omics data,
particularly those using MS (e.g. glycomics), to adopt the
mzTab model/design, CV infrastructure, and associated
software.
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